Clinical review report: Etonogestrel extended-release subdermal implant (Nexplanon) Merck Canada Inc. : indication: for the prevention of pregnancy
The objective of this report was to perform a systematic review of the beneficial and harmful effects of radiopaque etonogestrel extended-release subdermal implant 68 mg (Nexplanon) for the prevention of pregnancy in women
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
| Edition: | Version: Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of radiopaque etonogestrel extended-release subdermal implant 68 mg (Nexplanon) for the prevention of pregnancy in women |
|---|---|
| Physical Description: | 1 PDF file (78 pages) illustrations |